EBI3 and cancer: Additionally, just as PDL1 blockade alone does not target the activity of PD-L1+ exosomes, antibody blockade of Ebi3/IL-35 was not sufficient to reverse immunosuppression in murine cancer models (44), which may suggest the possibility that a strategy to target Ebi3+ EVs could more effectively reverse suppression within the tumor microenvironment.